ClinicalTrials.gg
Not yet recruitingNCT07840703Updated Sep 25, 2026

Symptomatic Hyperventilation in Individuals Living With Stroke

An observational study in Stroke and Hyperventilation Syndrome, sponsored by Istinye University. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Istinye University · Observational

How we know

Updated Sep 25, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
92
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Stroke by Istinye University — 5 open to participants now, 5 under way, none of them phase 3. Stroke · Istinye University.

Started
2026
with 3 others
Observational
4 of 13
4 open now
Registered
13th of 13
by date

Among the 13 studies in Stroke by Istinye University, this one is one of 4 that started in 2026, is one of 4 observational ones, and was the 13th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

5 of the 13 studies in Stroke by Istinye University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Stroke by Istinye University, or all of them as a file.
02

Study summary

This study will investigate the effects of hyperventilation syndrome on respiratory muscle strength, respiratory muscle endurance, pulmonary functions, and functional capacity in individuals living with stroke, and in this context, stroke patients with and without hyperventilation syndrome based on Nijmegen Questionnaire scores will be compared to evaluate the relationship between symptom burden and respiratory parameters.

03

Conditions studied

  • Stroke
  • Hyperventilation Syndrome

Browse trials for

Keywords

  • Stroke
  • Hyperventilation syndrome
  • Respiratory muscle strength
  • Respiratory muscle endurance
  • Pulmonary function
  • Functional capacity
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will comprise adult individuals diagnosed with stroke (ischaemic or haemorrhagic) who are in the post-stroke period. Participants will be recruited and screened based on the Nijmegen Questionnaire score to form two distinct cohorts: individuals presenting with symptomatic hyperventilation syndrome and individuals without hyperventilation syndrome.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals who will be diagnosed with a confirmed first-ever or recurrent stroke (ischaemic or haemorrhagic) verified by neuroimaging (CT or MRI).
  • Individuals who will be in the chronic or subacute post-stroke period (medically stable following stroke onset).
  • Individuals aged 18 years and older.
  • Individuals who will be classified into either the hyperventilation syndrome group based on a Nijmegen Questionnaire score of ≥23 or the control group based on a score of \<23.
  • Individuals who will be able to comprehend instructions and cooperate adequately with pulmonary function tests, respiratory muscle testing, and physical performance assessments.
  • Individuals who will provide written to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Individuals who will present with severe cognitive impairment, aphasia, or psychiatric disorders that will prevent reliable completion of questionnaires (such as the Nijmegen Questionnaire) or cooperation with test procedures.
  • Individuals who will have pre-existing primary (COPD), asthma, restrictive thoracic diseases, or other major pre-existing pulmonary pathologies that will confound pulmonary function test results.
  • Individuals who will have unstable cardiovascular conditions (e.g., recent myocardial infarction within the past 3-6 months, unstable angina pectoris, uncontrolled malignant arrhythmias, or uncontrolled severe hypertension) that will pose a risk during physical testing (such as the six-minute walk test).
  • Individuals who will have severe orthopedic, musculoskeletal, or lower extremity peripheral disorders unrelated to stroke that will independently limit functional capacity and walking distance (6MWD).
  • Individuals who will have active respiratory tract infections or acute pulmonary illnesses at the time of evaluation. Individuals who will be participating in an active pulmonary rehabilitation program or receiving respiratory muscle training concurrently.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
92 participants (estimated)
Patient registry
No

Groups and cohorts

  • Hyperventilation Syndrome Group

    Other: Respiratory Function, Respiratory Muscle Strength, and Functional Capacity Assessments

  • Without Hyperventilation Syndrome Group

    Other: Respiratory Function, Respiratory Muscle Strength, and Functional Capacity Assessments

Interventions

  • OtherRespiratory Function, Respiratory Muscle Strength, and Functional Capacity Assessments

    Both groups will undergo comprehensive evaluations including pulmonary function tests (FEV1, FVC, PEF), respiratory muscle strength (PImax, PEmax), respiratory muscle endurance tests, the Nijmegen Questionnaire, and the six-minute walk test (6MWT) to assess functional capacity.

06

What researchers measure

Primary outcomes

  1. Change in Forced Expiratory Volume in One Second (FEV1 % predicted)

    FEV1 percent predicted values will be measured to evaluate and compare pulmonary function between the hyperventilation syndrome group and the control group.

    Time frame: Measured at baseline/assessment

  2. Maximal inspiratory pressure (PImax)

    Maximal inspiratory pressure will be assessed to determine respiratory muscle strength.

    Time frame: Measured at baseline/assessment.

Secondary outcomes

  1. Maximal expiratory pressure (PEmax)

    Maximal expiratory pressure will be assessed to determine respiratory muscle strength.

    Time frame: Measured at baseline/assessment.

  2. Respiratory Muscle Endurance Score

    Respiratory muscle endurance scores will be recorded to evaluate breathing endurance between groups.

    Time frame: Measured at baseline/assessment.

  3. Forced Vital Capacity (FVC)

    FVC percentage value will be analyzed to assess restrictive patterns and flow rates.

    Time frame: Measured at baseline/assessment.

  4. Peak Expiratory Flow (PEF)

    PEF value will be analyzed to assess restrictive patterns and flow rates.

    Time frame: Measured at baseline/assessment.

  5. Six-Minute Walk Distance (6MWD)

    The six-minute walk test will be performed to measure functional capacity distance in meters.

    Time frame: Measured at baseline/assessment.

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Dec 2026, 2 months later.

Of 838 non-industry observational studies under Stroke, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 92. This study's planned 2 months is below that.

Counting every sponsor, half of 900 studies reached it within 40 months; a quarter within 18 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2026
First posted
Sep 25, 2026
StartEst.
Sep 25, 2026
Primary completionEst.
Dec 15, 2026
CompletionEst.
Dec 15, 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07840703
Lead sponsor
Istinye University
Responsible party
Yunus Emre Tutuneken (Dr. Assistant Professor, Istinye University) — Principal investigator
First posted
Sep 25, 2026
Start date
Sep 25, 2026 (estimated)
Primary completion
Dec 15, 2026 (estimated)
Completion
Dec 15, 2026 (estimated)
Last update
Sep 25, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion